Article
Adrenal crisis mainly manifested as recurrent syncope secondary to Tislelizumab:a case report and literature review
2023-08-23
Abstract excerpt
As immune checkpoint inhibitors (ICIs), Tislelizumab is an anti-programmed cell death protein 1 (PD-1) drug. With the extensive application of ICIs, there is an ever-increasing proportion of immune-related adverse events (irAEs) in clinic, some of which may even be life-threatening. Herein we present a patient of Tislelizumab-induced adrenal crisis. The main clinical manifestation is recurrent syncope accompanied...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 012fde26-ded2-536b-a4e3-d636040c9833
- DOI
- 10.21203/rs.3.rs-3234717/v1
